We are advancing innovative science and transformative medicines for people living with inflammatory and autoimmune diseases, including a portfolio of first in class programs and innovative development approaches across inflammatory bowel disease (IBD), respiratory, and rheumatological diseases.
Jnana Therapeutics – Collaboration to develop small molecules against multiple key regulators of cellular metabolism SLC transporters for selected targets in immunology and neurology.
Telavant – Acquisition to further develop and commercialise RVT-3101, a Phase-3 ready antibody with first-in-class and best-in-disease potential to treat patients suffering from IBD including ulcerative colitis (UC) and Crohn’s Disease and potentially multiple other immune-mediated diseases.
Qyuns – Global collaboration and license agreement with Qyuns Therapeutics to develop Qyuns’ anti-TSLP:IL33 bi-specific antibody for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Connect with our partnering experts to start the conversation.